Protagonist Therapeutics (PTGX) Short Interest Ratio & Short Volume $44.37 +0.03 (+0.07%) (As of 10/4/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Protagonist Therapeutics Short Interest DataProtagonist Therapeutics (PTGX) has a short interest of 3.23 million shares. This marks a -1.52% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.4, indicating that it would take 3.4 days of the average trading volume of 764,999 shares to cover all short positions.Current Short Interest3,230,000 sharesPrevious Short Interest3,280,000 sharesChange Vs. Previous Month-1.52%Dollar Volume Sold Short$151.87 millionShort Interest Ratio3.4 Days to CoverLast Record DateSeptember 15, 2024Outstanding Shares58,900,000 sharesPercentage of Shares Shorted5.48%Today's Trading Volume313,585 sharesAverage Trading Volume764,999 sharesToday's Volume Vs. Average41% Short Selling Protagonist Therapeutics? Sign up to receive the latest short interest report for Protagonist Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPTGX Short Interest Over TimePTGX Days to Cover Over TimePTGX Percentage of Float Shorted Over Time Ad Weiss RatingsWho are Nvidia’s New Silent Partners?Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.I call these Nvidia’s “Silent Partners.” Protagonist Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/20243,230,000 shares $151.87 million -1.5%N/A3.4 $47.02 8/31/20243,280,000 shares $140.68 million +5.8%N/A3.5 $42.89 8/15/20243,100,000 shares $125.83 million +6.9%N/A3.2 $40.59 7/31/20242,900,000 shares $108.58 million -11.0%N/A3.1 $37.44 7/15/20243,260,000 shares $119.81 million +59.8%N/A3.6 $36.75 6/30/20242,040,000 shares $70.69 million -34.6%N/A2.4 $34.65 Get the Latest News and Ratings for PTGX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 6/15/20243,120,000 shares $104.18 million -7.7%N/A5.3 $33.39 5/31/20243,380,000 shares $95.15 million -2.6%N/A5.8 $28.15 5/15/20243,470,000 shares $109.20 million -7.0%N/A6.3 $31.47 4/30/20243,730,000 shares $93.66 million +6.0%N/A6.6 $25.11 4/15/20243,520,000 shares $93.56 million +2.3%N/A5.2 $26.58 3/31/20243,440,000 shares $99.52 million +0.6%N/A4.6 $28.93 3/15/20243,420,000 shares $99.11 million +16.3%N/A4.7 $28.98 2/29/20242,940,000 shares $89.32 million +5.8%N/A3.6 $30.38 2/15/20242,780,000 shares $78.48 million +6.5%N/A3.5 $28.23 1/31/20242,610,000 shares $65.28 million +2.4%N/A3.2 $25.01 1/15/20242,550,000 shares $66.05 million +8.5%N/A3.5 $25.90 12/31/20232,350,000 shares $53.89 million -41.0%N/A3.3 $22.93 12/15/20233,980,000 shares $83.86 million +9.3%N/A5.6 $21.07 11/30/20233,640,000 shares $66.28 million -0.3%N/A5.4 $18.21 11/15/20233,650,000 shares $59.46 million -7.4%N/A5.7 $16.29 10/31/20233,940,000 shares $57.29 million +15.5%N/A6 $14.54 10/15/20233,410,000 shares $52.65 million +8.3%N/A5.3 $15.44 9/30/20233,150,000 shares $52.54 million +12.5%N/A4.5 $16.68 9/15/20232,800,000 shares $50.12 million +1.8%N/A3 $17.90 8/31/20232,750,000 shares $54.51 million -9.2%N/A2.8 $19.82 8/15/20233,030,000 shares $56.84 million +2.0%N/A2.8 $18.76 7/31/20232,970,000 shares $57.62 million -10.5%N/A2.7 $19.40 7/15/20233,320,000 shares $70.55 million +4.4%N/A2.8 $21.25 6/30/20233,180,000 shares $87.83 million +18.2%N/A2.7 $27.62 6/15/20232,690,000 shares $77.15 million -12.1%N/A2.5 $28.68 5/31/20233,060,000 shares $79.77 million -15.0%N/A2.5 $26.07 5/15/20233,600,000 shares $93.49 million -3.2%N/A2.2 $25.97 4/30/20233,720,000 shares $84.07 million -14.7%N/A2.2 $22.60 4/15/20234,360,000 shares $81.71 million +0.5%N/A2.5 $18.74 3/31/20234,340,000 shares $99.82 million -16.1%N/A2.6 $23.00 3/15/20235,170,000 shares $124.34 million +88.7%N/A3.2 $24.05 2/28/20232,740,000 shares $44.44 million +5.4%6.3%1.9 $16.22 2/15/20232,600,000 shares $42.43 million +2.0%6.0%2.5 $16.32 1/31/20232,550,000 shares $33.89 million +25.6%5.9%2.7 $13.29The Bible Says it Clear As Day (Ad)It came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This parable teaches us that it’s our duty, and our challenge, to grow our money … to invest it and put it to good use … rather than keeping it stuffed away in a savings account, or wasting it in some frivolous way. In this video, Wall Street expert Charles Mizrahi shows me a secret that has helped me … and tons of other hardworking Americans … learn to invest just like the pros on WallClick here to join me in the “Miracle on Main Street.” 1/15/20232,030,000 shares $24.71 million +14.0%4.7%2.4 $12.17 12/30/20221,780,000 shares $19.42 million -4.3%4.1%2.3 $10.91 12/15/20221,860,000 shares $17.73 million +6.9%4.3%2.4 $9.53 11/30/20221,740,000 shares $13.76 million -4.4%4.0%2.2 $7.91 11/15/20221,820,000 shares $14.63 million -7.6%4.2%2.4 $8.04 10/31/20221,970,000 shares $15.96 million -11.7%4.5%2.5 $8.10 10/15/20222,230,000 shares $17.82 million -8.2%5.1%2.6 $7.99 9/30/20222,430,000 shares $20.48 million -13.5%5.6%2.7 $8.43 9/15/20222,810,000 shares $23.24 million +9.3%6.5%2.8 $8.27 8/31/20222,570,000 shares $22.41 million -11.4%5.9%2.4 $8.72 8/15/20222,900,000 shares $32.86 million -31.6%6.7%2.7 $11.33 7/31/20224,240,000 shares $42.19 million -13.1%N/A3.5 $9.95 7/15/20224,880,000 shares $46.16 million +2.3%N/A3.5 $9.46 6/30/20224,770,000 shares $37.73 million +18.4%N/A3.4 $7.91 6/15/20224,030,000 shares $30.14 million +18.9%N/A3 $7.48 5/31/20223,390,000 shares $29.70 million +1.5%N/A2.9 $8.76 5/15/20223,340,000 shares $29.43 million +1.5%N/A2.9 $8.81 4/30/20223,290,000 shares $29.91 million +20.5%N/A3.1 $9.09 4/15/20222,730,000 shares $54.46 million -16.3%N/A3.3 $19.95 3/31/20223,260,000 shares $77.20 million -17.5%N/A4.6 $23.68 3/15/20223,950,000 shares $101.99 million -0.8%N/A5.7 $25.82 2/28/20223,980,000 shares $96.63 million -19.1%N/A5.6 $24.28 2/15/20224,920,000 shares $141.35 million +25.5%N/A7.3 $28.73 1/31/20223,920,000 shares $114.82 million +9.5%N/A6.4 $29.29 1/15/20223,580,000 shares $128.74 million +10.2%N/A5.9 $35.96 12/31/20213,250,000 shares $111.15 million +2.2%N/A2.4 $34.20 12/15/20213,180,000 shares $97.12 million +2.6%N/A2.2 $30.54 11/30/20213,100,000 shares $104.22 million -17.6%7.3%1.6 $33.62 11/15/20213,760,000 shares $134.38 million -15.1%8.8%1.9 $35.74 10/29/20214,430,000 shares $138.04 million +18.5%10.5%2.3 $31.16 10/15/20213,740,000 shares $115.83 million +2.8%8.9%2 $30.97 9/30/20213,640,000 shares $64.50 million +27.3%8.7%2.1 $17.72 9/15/20212,860,000 shares $132.90 million -6.5%6.8%3 $46.47 8/31/20213,060,000 shares $148.41 million -4.4%7.3%7.3 $48.50 8/13/20213,200,000 shares $152.61 million +5.6%7.6%7.3 $47.69 7/30/20213,030,000 shares $149.77 million -11.1%7.3%6.9 $49.43 7/15/20213,410,000 shares $150.93 million -1.7%8.3%8.1 $44.26 6/30/20213,470,000 shares $155.73 million -1.4%8.5%8.5 $44.88 6/15/20213,520,000 shares $134.29 million -3.8%8.6%9.3 $38.15 5/28/20213,660,000 shares $128.50 million -6.2%9.7%11.6 $35.11 5/14/20213,900,000 shares $113.10 million +26.2%N/A12.2 $29.00 4/30/20213,090,000 shares $92.67 million +1.6%N/A9.2 $29.99 4/15/20213,040,000 shares $79.01 million +0.3%N/A9.1 $25.99 3/31/20213,030,000 shares $76.69 million +5.6%N/A8.5 $25.31 3/15/20212,870,000 shares $88.97 million +3.6%N/A6.4 $31.00 2/26/20212,770,000 shares $66.45 million -0.4%N/A5.6 $23.99 2/12/20212,780,000 shares $69.75 million +1.5%N/A5.9 $25.09 1/29/20212,740,000 shares $58.25 million -13.6%N/A5.7 $21.26 1/15/20213,170,000 shares $72.43 million -7.9%N/A6.6 $22.85 12/31/20203,440,000 shares $68.77 million +28.4%N/A7.6 $19.99The Bible Says it Clear As Day (Ad)It came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This parable teaches us that it’s our duty, and our challenge, to grow our money … to invest it and put it to good use … rather than keeping it stuffed away in a savings account, or wasting it in some frivolous way. In this video, Wall Street expert Charles Mizrahi shows me a secret that has helped me … and tons of other hardworking Americans … learn to invest just like the pros on WallClick here to join me in the “Miracle on Main Street.” 12/15/20202,680,000 shares $56.07 million +6.8%N/A6.6 $20.92 11/30/20202,510,000 shares $59.86 million -1.6%N/A6.9 $23.85 11/15/20202,550,000 shares $56.64 million No ChangeN/A7.2 $22.21 10/30/20202,550,000 shares $47.15 million -6.9%N/A7.2 $18.49 10/15/20202,740,000 shares $57.46 million -16.5%N/A7.9 $20.97 9/30/20203,280,000 shares $64.12 million +45.8%N/A9.5 $19.55 9/15/20202,250,000 shares $48.74 million +16.0%N/A6.3 $21.66 8/31/20201,940,000 shares $43.46 million +12.1%N/A5.4 $22.40 8/14/20201,730,000 shares $27.14 million +8.8%N/A4.2 $15.69 7/31/20201,590,000 shares $25.01 million +15.2%N/A2.8 $15.73 7/15/20201,380,000 shares $21.51 million +4.6%N/A1.3 $15.59 6/30/20201,320,000 shares $23.31 million -9.6%N/A1.2 $17.66 6/15/20201,460,000 shares $23.51 million +29.2%N/A1.4 $16.10 5/29/20201,130,000 shares $18.69 million -11.7%N/A1.2 $16.54 5/15/20201,280,000 shares $20.74 million +14.3%N/A1.4 $16.20 4/30/20201,120,000 shares $7.56 million -13.9%5.4%1.5 $6.75 4/15/20201,300,000 shares $8.87 million +4.0%6.3%8.6 $6.82 3/31/20201,250,000 shares $8.14 million -8.2%6.1%7.5 $6.51 3/13/20201,362,300 shares $9.47 million +14.5%7.0%9.5 $6.95 2/28/20201,190,000 shares $7.14 million -11.9%6.1%5.7 $6.00 2/14/20201,350,000 shares $10.30 million +3.9%6.9%2.1 $7.63 1/31/20201,300,000 shares $10.82 million +4.8%6.9%2 $8.32 1/15/20201,240,000 shares $10.39 million -20.5%6.5%1.9 $8.38 12/31/20191,560,000 shares $11.73 million +39.3%8.2%2.4 $7.52 PTGX Short Interest - Frequently Asked Questions What is Protagonist Therapeutics' current short interest? Short interest is the volume of Protagonist Therapeutics shares that have been sold short but have not yet been covered or closed out. As of September 15th, traders have sold 3,230,000 shares of PTGX short. Learn More on Protagonist Therapeutics' current short interest. What is a good short interest ratio for Protagonist Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PTGX shares currently have a short interest ratio of 3.0. Learn More on Protagonist Therapeutics's short interest ratio. Which institutional investors are shorting Protagonist Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Protagonist Therapeutics: Susquehanna International Group LLP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Protagonist Therapeutics' short interest increasing or decreasing? Protagonist Therapeutics saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 3,230,000 shares, a decrease of 1.5% from the previous total of 3,280,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Protagonist Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Protagonist Therapeutics: Amphastar Pharmaceuticals, Inc. (11.43%), Calliditas Therapeutics AB (publ) (0.01%), Phibro Animal Health Co. (2.06%), Esperion Therapeutics, Inc. (19.62%), Cara Therapeutics, Inc. (2.64%), Qiagen (1.58%), Legend Biotech Co. (5.74%), Ascendis Pharma A/S (5.74%), Roivant Sciences Ltd. (9.02%), Intra-Cellular Therapies, Inc. (2.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Canadian Natural Resources Limited ($6.15 billion), Charter Communications, Inc. ($4.04 billion), Paychex, Inc. ($2.77 billion), Nu Holdings Ltd. ($2.71 billion), Cencora, Inc. ($2.34 billion), Aptiv PLC ($2.18 billion), Tractor Supply ($2.07 billion), International Paper ($2.01 billion), AppLovin Co. ($1.95 billion), and Moderna, Inc. ($1.89 billion). View all of the most shorted stocks. What does it mean to sell short Protagonist Therapeutics stock? Short selling PTGX is an investing strategy that aims to generate trading profit from Protagonist Therapeutics as its price is falling. PTGX shares are trading up $0.18 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Protagonist Therapeutics? A short squeeze for Protagonist Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PTGX, which in turn drives the price of the stock up even further. How often is Protagonist Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTGX, twice per month. The most recent reporting period available is September, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Amphastar Pharmaceuticals Short Interest Calliditas Therapeutics AB (publ) Short Interest Phibro Animal Health Short Interest Esperion Therapeutics Short Interest Cara Therapeutics Short Interest Qiagen Short Interest Legend Biotech Short Interest Ascendis Pharma A/S Short Interest Roivant Sciences Short Interest Intra-Cellular Therapies Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PTGX) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersThe panic button has already been pressedIf you missed it, my emergency election broadcast is now available on replay.Porter & Company | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed ...InvestorPlace | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.